JP6976244B2 - 心臓状態および他の病態の処置のための複数の生物学的に活性なポリペプチドを単一のベクターから発現させるための組成物および方法 - Google Patents

心臓状態および他の病態の処置のための複数の生物学的に活性なポリペプチドを単一のベクターから発現させるための組成物および方法 Download PDF

Info

Publication number
JP6976244B2
JP6976244B2 JP2018524443A JP2018524443A JP6976244B2 JP 6976244 B2 JP6976244 B2 JP 6976244B2 JP 2018524443 A JP2018524443 A JP 2018524443A JP 2018524443 A JP2018524443 A JP 2018524443A JP 6976244 B2 JP6976244 B2 JP 6976244B2
Authority
JP
Japan
Prior art keywords
seq
polypeptide
polynucleotide
linker
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018524443A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536405A5 (enExample
JP2018536405A (ja
Inventor
エス． パテール，ディムキ
エヌ． パテール，アミット
Original Assignee
プレシゲン，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プレシゲン，インコーポレイテッド filed Critical プレシゲン，インコーポレイテッド
Publication of JP2018536405A publication Critical patent/JP2018536405A/ja
Publication of JP2018536405A5 publication Critical patent/JP2018536405A5/ja
Application granted granted Critical
Publication of JP6976244B2 publication Critical patent/JP6976244B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1738—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4728—Calcium binding proteins, e.g. calmodulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018524443A 2015-11-11 2016-11-11 心臓状態および他の病態の処置のための複数の生物学的に活性なポリペプチドを単一のベクターから発現させるための組成物および方法 Expired - Fee Related JP6976244B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562254139P 2015-11-11 2015-11-11
US62/254,139 2015-11-11
PCT/US2016/061668 WO2017083750A1 (en) 2015-11-11 2016-11-11 Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies

Publications (3)

Publication Number Publication Date
JP2018536405A JP2018536405A (ja) 2018-12-13
JP2018536405A5 JP2018536405A5 (enExample) 2019-12-19
JP6976244B2 true JP6976244B2 (ja) 2021-12-08

Family

ID=57543150

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018524443A Expired - Fee Related JP6976244B2 (ja) 2015-11-11 2016-11-11 心臓状態および他の病態の処置のための複数の生物学的に活性なポリペプチドを単一のベクターから発現させるための組成物および方法

Country Status (14)

Country Link
US (3) US11154622B2 (enExample)
EP (1) EP3387010A1 (enExample)
JP (1) JP6976244B2 (enExample)
KR (1) KR20180069081A (enExample)
CN (1) CN108713025A (enExample)
AU (1) AU2016353342B2 (enExample)
BR (1) BR112018009645A2 (enExample)
CA (1) CA3004742A1 (enExample)
HK (1) HK1259137A1 (enExample)
MA (1) MA43404A (enExample)
MX (1) MX2018005886A (enExample)
RU (1) RU2758489C2 (enExample)
SG (1) SG11201803934YA (enExample)
WO (1) WO2017083750A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102673203B1 (ko) 2016-04-20 2024-06-10 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. Pklr의 유전자 발현 증강을 위한 조성물 및 방법
CA3049652A1 (en) 2017-01-10 2018-07-19 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
JP7240749B2 (ja) 2017-09-29 2023-03-16 ベスファジェン・インコーポレイテッド 心不全の予防または治療のための医薬組成物
AU2018352583B2 (en) 2017-10-16 2025-04-17 Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. Lentiviral vectors for delivery of PKLR to treat Pyruvate Kinase Deficiency
SG11202008539YA (en) 2018-03-06 2020-10-29 Precigen Inc Human papillomavirus vaccines and uses of the same
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
US12539316B2 (en) 2018-04-11 2026-02-03 Spacecraft Seven, Llc Compositions and methods for stem cell transplant
IL278213B2 (en) 2018-04-27 2026-04-01 Rocket Pharmaceuticals Ltd A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)
CA3100070A1 (en) * 2018-05-18 2019-11-21 Universite Laval Vectors for dna vaccination
US12528848B2 (en) * 2018-05-25 2026-01-20 The Wistar Institute Of Anatomy And Biology Tumor-specific neoantigens and methods of using the same
IL280465B2 (en) 2018-07-30 2025-03-01 Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P Methods for gene modification of hematopoietic cells
BR112021006182A2 (pt) 2018-10-01 2021-06-29 Adicet Bio, Inc. composições e métodos relativos a células t¿d,d engenheiradas e não engenheiradas para tratamento de tumores hematológicos
US12698340B2 (en) 2018-10-01 2026-08-04 Adicet Therapeutics, Inc. Compositions and methods regarding engineered and non-engineered γδ T-cells for treatment of solid tumors
KR102985320B1 (ko) * 2019-03-29 2026-07-06 아비오메드, 인크. 생물학 요법 또는 벡터 유전자 요법에서 좌심실 언로딩을 위한 시스템 및 방법
CN114450411A (zh) 2019-04-01 2022-05-06 特纳亚治疗股份有限公司 具有工程化衣壳的腺相关病毒
WO2020232527A1 (en) * 2019-05-21 2020-11-26 UNIVERSITé LAVAL Crimean-congo hemorrhagic fever virus immunogenic compositions
CN114173863A (zh) * 2019-08-07 2022-03-11 西北大学 用于在心脏中基因递送的材料和方法
TWI897882B (zh) * 2019-09-20 2025-09-21 英商Ｕｃｌ商業有限責任公司 右心室心律失常性心肌病之基因療法組合物及治療
AU2021259422A1 (en) 2020-04-20 2022-12-08 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
WO2022032226A1 (en) * 2020-08-07 2022-02-10 Spacecraft Seven, Llc Plakophilin-2 (pkp2) gene therapy using aav vector
JP7415042B2 (ja) 2020-10-09 2024-01-16 テナヤ セラピューティクス， インコーポレイテッド プラコフィリン２遺伝子治療の方法および組成物
US11781156B2 (en) * 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
MX2024001939A (es) * 2021-08-12 2024-07-10 Univ Temple Administracion retrograda de composicion terapeutica mediante seno o vena coronarios.
AU2023281902A1 (en) * 2022-06-02 2024-11-28 Hugo A. Katus S100a1 protein for use in treating and preventing infarct extension

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4985461A (en) 1985-10-21 1991-01-15 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
US5117057A (en) 1985-10-21 1992-05-26 Rohm And Haas Company Insecticidal N' substituted-N-N'-disubstituted-hydrazines
US5225443A (en) 1986-05-01 1993-07-06 Rohm And Haas Company Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
IL100643A (en) 1991-01-25 1996-10-31 Nippon Kayaku Kk History of hydrazine and pesticides containing these histories as an active ingredient
US5530028A (en) 1992-11-23 1996-06-25 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
US6013836A (en) 1992-02-28 2000-01-11 Rohm And Haas Company Insecticidal N'-substituted-N,N'-disubstitutedhydrazines
WO2001070816A2 (en) 2000-03-22 2001-09-27 Rohm And Haas Company Ecdysone receptor-based inducible gene expression system
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
CA2438119C (en) 2001-02-20 2014-12-16 Rheogene Holdings, Inc. Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system
AU2002306550B2 (en) 2001-02-20 2007-10-25 Intrexon Corporation Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
EP1534738B1 (en) 2001-02-20 2012-06-20 Intrexon Corporation Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
ES2385598T3 (es) 2001-02-20 2012-07-27 Intrexon Corporation Sistema novedoso de expresión génica inducible basado en el receptor de ecdisona/receptor X retinoide de invertebrado
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
JP2005532781A (ja) 2001-09-26 2005-11-04 レオジーン・ホールディングス，インコーポレーテッド ヨコバイエクジソン受容体核酸、ポリペプチド、およびそれらの使用
EP1490686A2 (en) 2001-09-26 2004-12-29 RheoGene Holdings Inc. Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
US7375093B2 (en) 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7304161B2 (en) 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7304162B2 (en) 2003-02-21 2007-12-04 Intrexon Corporation Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US9034650B2 (en) 2005-02-02 2015-05-19 Intrexon Corporation Site-specific serine recombinases and methods of their use
AU2007332980A1 (en) 2006-07-26 2008-06-19 Intrexon Corporation Methods and compositions for treating disease
US7719424B2 (en) 2007-01-19 2010-05-18 Igt Table monitoring identification system, wager tagging and felt coordinate mapping
MX363066B (es) 2007-05-29 2019-03-07 Intrexon Corp Ligandos quirales de diacilhidrazina para modular la expresion de genes exogenos por medio de un complejo receptor de ecdisona.
US20090136465A1 (en) 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
JP2010539993A (ja) 2007-10-08 2010-12-24 イントレキソン コーポレーション 遺伝子操作した樹状細胞および癌の治療のための使用
US8236527B2 (en) * 2008-03-14 2012-08-07 Humanzyme Limited Recombinant production of authentic human proteins using human cell expression systems
MX340972B (es) 2008-10-08 2016-08-02 Intrexon Corp Celulas manipuladas por ingenieria que expresan multiples inmunomoduladores, y uso de las mismas.
CA2772610C (en) 2009-08-28 2018-01-23 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
EP2550359B1 (en) 2010-03-23 2017-08-09 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
EP2681327B1 (en) 2011-03-04 2018-11-21 Intrexon Corporation Vectors conditionally expressing protein
HUE051277T2 (hu) * 2012-11-16 2021-03-01 United Biomedical Inc Szintetikus peptiden alapuló sürgõsségi vakcina ragadós száj- és körömfájás (FMD) ellen
WO2014089121A2 (en) * 2012-12-03 2014-06-12 Thomas Ichim Retrograde delivery of cells and nucleic acids for treatment of cardiovascular diseases
WO2014145199A2 (en) 2013-03-15 2014-09-18 The Cleveland Clinic Foundation Retrograde delivery of sdf-1 for treatment of myocardial infarction
WO2016187585A1 (en) 2015-05-20 2016-11-24 Viventia Bio Inc. Deimmunized linker and methods of use
CN105754990A (zh) * 2016-01-29 2016-07-13 深圳精准医疗科技有限公司 一种pd-1/ctla-4双特异性抗体的制备方法及其应用

Also Published As

Publication number Publication date
US20240148908A1 (en) 2024-05-09
US20180360992A1 (en) 2018-12-20
HK1259137A1 (zh) 2019-11-29
US20220072159A1 (en) 2022-03-10
US11154622B2 (en) 2021-10-26
JP2018536405A (ja) 2018-12-13
RU2758489C2 (ru) 2021-10-28
CN108713025A (zh) 2018-10-26
CA3004742A1 (en) 2017-05-18
RU2018117674A3 (enExample) 2020-04-20
EP3387010A1 (en) 2018-10-17
SG11201803934YA (en) 2018-06-28
BR112018009645A2 (pt) 2018-11-13
MA43404A (fr) 2018-10-17
AU2016353342A1 (en) 2018-05-24
RU2018117674A (ru) 2019-12-13
KR20180069081A (ko) 2018-06-22
WO2017083750A1 (en) 2017-05-18
AU2016353342B2 (en) 2021-04-01
MX2018005886A (es) 2018-08-15

Similar Documents

Publication Publication Date Title
US20240148908A1 (en) Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies
US20230340528A1 (en) Methods of treating cardiac disorders and congestive heart failure and administering aav vectors
EP2494058B1 (en) Cardiac-specific nucleic acid regulatory elements and methods and use thereof
JP7737385B2 (ja) 遺伝子療法のためのａａｖ２をベースとするウイルスベクター粒子
US10729789B2 (en) Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells
US20160166651A1 (en) Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunctions and congestive heart failure
CN108342363B (zh) 共表达抗msln嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途
US20240082357A1 (en) Compositions and methods for the treatment of ischemia and cardiomyopathy
WO2017029206A1 (en) Use of k2p potassium channel for altering the electrophysiology of the heart
CN119947741A (zh) 使用艾帕素治疗淋巴水肿
JP2024530019A (ja) ヒト心臓リプログラミングを増強させるための短縮型ｐ６３タンパク質ドメイン
WO2022066714A2 (en) Delivery of sfrp-3 or foxm1 inhibitor to protect from and treat mitral regurgitation and heart failure
EP3658676B1 (en) Endothelial-specific promoter sequences and uses thereof
JP2022515211A (ja) 合成マイクロｒｎａミミック
CN120758566B (zh) 一种在心肌细胞中特异性过表达zer1的病毒载体的构建及在心衰治疗中的应用
WO2026046351A1 (en) Circular rna encoding vegf polypeptides, formulations, and methods of uses
CN101532027A (zh) 缺氧诱导真核基因表达载体及其用途
Shams EGLN1 Targeted SpCas9 Encapsulating VLPs for Proangiogenic Cascade Activation and Their Delivery via Alginate Hydrogels
EP3689896A1 (en) Grk2 modulating mirnas
Sasipong Targeted overexpression of relaxin receptor 1 (RXFP1) with chronic administration of relaxin as a novel inotropic approach for heart failure treatment
HK40090887A (en) Methods of treating cardiac disorders and congestive heart failure and administering aav vectors
Trampel et al. RNAi-mediated p38δ silencing mitigates anthracycline cardiotoxicity in female mice
Li et al. Construction of the pEGFP-N1-p53/MAR Vector and Its Effect on HEP3B Cell Morphology

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210521

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211019

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211109

R150 Certificate of patent or registration of utility model

Ref document number: 6976244

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees